bluebird bio sells second Priority Review Voucher

US biotech bluebird bio (Nasdaq: BLUE) on Friday announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV).

The company disclosed the name of the buyer as Bristol Myers Squibb (NYSE: BMY), in a Securities and Exchange Commission filing, and said that the US pharma major paid $95 million for the voucher. This follows the sale of the company’s first PRV in December for $102 million. In the past, PRVs have sold for more than $300 million, with the new prices indicating that their rarity value has fallen significantly. Bluebird shares closed down 1% on the news.

bluebird bio was granted two PRVs along with the US Food and Drug Administration (FDA) approvals of Zynteglo (betibeglogene autotemcel) for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively.